Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent beta-lactam dosing in severe sepsis ICU patients
ACTRN12612000138886Phase 2Completed
- Sponsor
- National Health and Medical Research Council
- Start
- Jul 2012
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ticarcillin plus clavulanic acid, meropenem, piperacillin + tazobactam, flucloxacillin and dicloxacillin in sepsis and bacterial disease (2 arms), sponsored by National Health and Medical Research Council. Primary endpoint: ICU-free days up to Day 28. Started Jul 2012; status: completed.
02
Drugs
ticarcillin plus clavulanic acidmeropenempiperacillin + tazobactamflucloxacillindicloxacillin
03
Conditions
sepsisbacterial disease
Beyond the preview
Go deeper on ACTRN12612000138886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000138886.